AIM Immunotech vs Altimmune
AIM Immunotech is the larger business, with $88,000 of revenue in fiscal 2025 against $41,000 for Altimmune (2.1 times as much). Altimmune grew faster (105.0% against -48.2%). AIM Immunotech kept more of each dollar of sales as profit: a net margin of -15861.4% against -214861.0%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | AltimmuneALT, 2025 |
|---|---|---|
| Revenue | $88,000 | $41,000 |
| Revenue growth | -48.2% | 105.0% |
| Net income | −$14.0m | −$88.1m |
| Operating margin | -13254.5% | — |
| Net margin | -15861.4% | -214861.0% |
| Return on equity | — | -50.6% |
| Free cash flow | −$11.0m | −$67.5m |
| Cash | $3.0m | $43.8m |
| Total debt | $8.0m | $35.0m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 57 |
| Market value | $4.7m | $398m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 6 buys, 0 sales | 11 buys, 0 sales |